Randomized controlled trial to investigate the retention time of intravesical instillation therapy with pirarubicin for non-muscule invasive bladder cancer following transurethral resection of bladder tumor.
Phase 3
Recruiting
- Conditions
- Intermediate risk non-muscle invasive bladder cancer
- Registration Number
- JPRN-UMIN000006861
- Lead Sponsor
- Kumamoto Univeristy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who previously underwent intravesical therapy with BCG. 2. The patients underwent maintenance intravesical therapy of an anticancer agent. 3. Patients with active other malignant disease. 4. Patients with historically or presently disease of upper urinary tract urothelial cell carcinoma. 5. Funcion of all organs are without severe dysfunction. 6. Inappropriate patients for this study judged by the physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of life
- Secondary Outcome Measures
Name Time Method Safety Recurrence-free rate